Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Anna Adam-Artigues"'
Autor:
Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Federico Rojo, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Lluch, Begoña Bermejo, Felix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez, Pilar Eroles
Publikováno v:
Cancer Communications, Vol 42, Iss 12, Pp 1412-1416 (2022)
Externí odkaz:
https://doaj.org/article/7c968fc3805d4bed95fdb0851caa2240
Autor:
Birlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, Eduardo Tormo, Begoña Pineda, Paula Cabello, Elisa Alonso, Begoña Bermejo, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Federico Rojo, Octavio Burgués, Juan Miguel Cejalvo, Ana Lluch, Pilar Eroles
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of
Externí odkaz:
https://doaj.org/article/116915f38b83493fb827155096227e7d
Autor:
Cristina Hernando, Belén Ortega-Morillo, Marta Tapia, Santiago Moragón, María Teresa Martínez, Pilar Eroles, Iris Garrido-Cano, Anna Adam-Artigues, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 15, p 7812 (2021)
Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine therapy is the fundamental treatment against this entity, by directly or indirectly modifying estrogen production. Recent advances in novel compounds, such as cyc
Externí odkaz:
https://doaj.org/article/4ce42704a1264f0aa38a397025d47661
Autor:
Iris Garrido-Cano, Vera Constâncio, Anna Adam-Artigues, Ana Lameirinhas, Soraya Simón, Belen Ortega, María Teresa Martínez, Cristina Hernando, Begoña Bermejo, Ana Lluch, Paula Lopes, Rui Henrique, Carmen Jerónimo, Juan Miguel Cejalvo, Pilar Eroles
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 19, p 7427 (2020)
MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnos
Externí odkaz:
https://doaj.org/article/fb9f89c5132d44ec94f3c2b0577c86bd
Autor:
Anna Adam-Artigues, Enrique J. Arenas, Alex Martínez-Sabadell, Fara Brasó-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, María Teresa Martínez, Juan Carbonell-Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Aleix Prat, Joaquín Arribas, Pilar Eroles, Juan Miguel Cejalvo
Publikováno v:
Science Advances
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Scientia
Breast cancer; Heterodimerization Cáncer de mama; Heterodimerización Càncer de mama; Heterodimerització Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06fb8c5eed3e6e740807833312138fdd
http://hdl.handle.net/2445/197295
http://hdl.handle.net/2445/197295
Autor:
Iris Garrido-Cano, Pilar Eroles, Birlipta Pattanayak, Raimundo Cervera, Ana Lameirinhas, Sandra Torres-Ruiz, Eduardo Tormo, Anna Adam-Artigues
Publikováno v:
Cancer and Metastasis Reviews. 41:77-105
Breast cancer is the most frequent cancer in women worldwide. Despite the improvement in diagnosis and treatments, the rates of cancer relapse and resistance to therapies remain higher than desirable. Alterations in microRNAs have been linked to chan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2efc685c770470709d306586da48b175
https://doi.org/10.1007/s10555-021-09992-0
https://doi.org/10.1007/s10555-021-09992-0
Autor:
Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, Jaume Forés-Martos, María Teresa Martínez, Cristina Hernando, Sandra Zazo, Juan Madoz-Gúrpide, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo, Pilar Eroles
Publikováno v:
Cancers; Volume 15; Issue 7; Pages: 2138
Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c17f0f958e9898f8597214c05cc99fc7
https://doi.org/10.3390/cancers15072138
https://doi.org/10.3390/cancers15072138
Autor:
Rui Henrique, Begoña Bermejo, Soraya Simón, Belen Ortega, Pilar Eroles, Vera Constâncio, Carmen Jerónimo, Paula Lopes, Ana Lameirinhas, M. I. Martínez, Anna Adam-Artigues, Iris Garrido-Cano, Cristina Hernando, Ana Lluch, Juan Miguel Cejalvo
Publikováno v:
Cancer Research. 81:PS2-31
BACKGROUND: MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analyzed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally inva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6a2d082a072d398c8fdcba58a6715ff
https://doi.org/10.1158/1538-7445.sabcs20-ps2-31
https://doi.org/10.1158/1538-7445.sabcs20-ps2-31
Autor:
María Teresa Martínez, Marta Tapia, Lina Candia, Begoña Bermejo, Iris Garrido-Cano, Anna Adam-Artigues, Pilar Eroles, Ana Lluch, Inmaculada de Juan, Estela Contel, Cristina Hernando, Sara S Oltra, Juan M. Cejalvo, Isabel Chirivella
Publikováno v:
Journal of Cancer Science and Clinical Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c313d444aab0f63b075a777c517ba877
https://doi.org/10.26502/jcsct.5079162
https://doi.org/10.26502/jcsct.5079162
Autor:
S. Moragón, Pilar Eroles, Marta Tapia, Ana Lluch, Belén Ortega-Morillo, Begoña Bermejo, Anna Adam-Artigues, Iris Garrido-Cano, M. I. Martínez, Cristina Hernando, Juan Miguel Cejalvo
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 7812, p 7812 (2021)
International Journal of Molecular Sciences, Vol 22, Iss 7812, p 7812 (2021)
Estrogen receptor-positive (ER+) is the most common subtype of breast cancer. Endocrine therapy is the fundamental treatment against this entity, by directly or indirectly modifying estrogen production. Recent advances in novel compounds, such as cyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15eda0118751b77e952c06ab1e9f7b6a
https://pubmed.ncbi.nlm.nih.gov/34360578
https://pubmed.ncbi.nlm.nih.gov/34360578